Brickell Biotech, Inc. (BBI) Stock Analysis
DELISTED 2022
What happened to Brickell Biotech, Inc. (BBI) stock?
Brickell Biotech, Inc. (BBI) no longer trades on public markets. It was delisted in September 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Brickell Biotech, Inc. (BBI) trades at $2.35. Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing prescription therapeutics for autoimmune, inflammatory, and other debilitating diseases. Market cap: $7.08M, Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for BBI: BBI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BBI against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
BBI: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Brickell Biotech, Inc. (BBI) Healthcare & Pipeline Overview
Brickell Biotech is a clinical-stage biopharmaceutical company specializing in therapeutics for autoimmune and inflammatory diseases, with a focus on dermatology. Their lead asset, sofpironium bromide, targets hyperhidrosis, positioning them in a niche market within the broader dermatology sector. The company also has early-stage assets targeting other inflammatory conditions.
What Is the Investment Thesis for BBI?
Brickell Biotech presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biopharmaceutical companies. The primary value driver is sofpironium bromide and its potential approval and commercial success in treating primary axillary hyperhidrosis. Positive Phase III trial results provide a foundation, but regulatory approval and market penetration remain uncertain. The company's early-stage pipeline, including BBI-02 and BBI-10, offers longer-term growth potential but carries significant development risk. With a market cap of approximately $0.01 billion and negative profitability (P/E of -0.97 and a profit margin of -71.1%), the company's valuation is highly dependent on clinical and regulatory milestones. Investors should carefully consider the risks associated with drug development, regulatory hurdles, and market competition.
Based on FMP financials and quantitative analysis
BBI Key Highlights
Sofpironium bromide has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis.
- Gross Margin of 100.0% indicates strong potential profitability upon commercialization, although this is currently offset by high R&D expenses.
- Market Cap of $7.08M reflects the company's early stage and associated risks.
- P/E Ratio of -0.97 indicates the company is currently unprofitable.
- The company has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc.
Who Are BBI's Competitors?
BBI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CSCI COSCIENS Biopharma Inc. | $2.72 | +0.00% | $8.57M | 63 |
| ENTO ENTO | $2.85 | -5.00% | $13.6M | 49 |
| KA Kineta, Inc. | $0.57 | -30.77% | $7.05M | 45 |
| OMGA Omega Therapeutics, Inc. | $0.14 | +0.00% | $7.90M | 54 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BBI's Key Strengths?
Promising late-stage asset (sofpironium bromide) with positive Phase III results.
- Focus on specific therapeutic areas with unmet needs.
- Strategic collaborations with established companies.
- Innovative pipeline of drug candidates.
What Are BBI's Weaknesses?
Limited financial resources and reliance on external funding.
- High dependence on the success of sofpironium bromide.
- Early-stage pipeline with significant development risks.
- Small number of employees.
What Could Drive BBI Stock Higher?
Potential FDA approval and commercial launch of sofpironium bromide for primary axillary hyperhidrosis.
- Advancement of BBI-02 into clinical trials for autoimmune and inflammatory diseases.
- Continued progress in preclinical development of BBI-10 for autoinflammatory and rare genetic diseases.
What Are the Key Risks for BBI?
Financial-distress signal — its Altman Z-Score of -7.21 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-66.5%) — the business is not currently generating profit on shareholder capital.
- Failure to obtain regulatory approval for sofpironium bromide.
- Unfavorable clinical trial results for BBI-02 or BBI-10.
- Competition from other companies developing treatments for hyperhidrosis and autoimmune diseases.
- Dependence on external funding and potential dilution of shareholder value.
What Are the Growth Opportunities for BBI?
- Sofpironium Bromide Commercialization: The successful commercialization of sofpironium bromide for primary axillary hyperhidrosis represents a significant growth opportunity. Securing regulatory approval and establishing effective marketing and distribution channels are critical for capturing market share. The timeline for this growth opportunity is dependent on regulatory review and approval processes.
- Expansion of Sofpironium Bromide Indications: Beyond primary axillary hyperhidrosis, exploring additional indications for sofpironium bromide, such as other forms of hyperhidrosis or related dermatological conditions, could expand its market potential. This strategy would require further clinical trials and regulatory approvals, extending the timeline but potentially yielding substantial returns.
- Advancement of BBI-02 (DYRK1A Inhibitor): Developing BBI-02, an oral DYRK1A inhibitor, for the treatment of autoimmune and inflammatory diseases offers a broader therapeutic scope. The autoimmune disease market is a multi-billion dollar market. Progressing BBI-02 through clinical trials and demonstrating efficacy and safety are essential for realizing this growth opportunity. This represents a longer-term growth driver with inherent clinical development risks.
- Development of BBI-10 (STING Inhibitor): The development of BBI-10, a covalent stimulator of interferon genes (STING) inhibitor, for autoinflammatory and rare genetic diseases, represents another avenue for growth. The market for rare genetic disease therapies is expanding, driven by increased awareness and regulatory incentives. Success depends on preclinical and clinical studies demonstrating the drug's effectiveness and safety.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with larger pharmaceutical companies or pursuing targeted acquisitions could accelerate the development and commercialization of Brickell Biotech's pipeline. Collaborations can provide access to funding, expertise, and distribution networks, while acquisitions can expand the company's portfolio and market reach. The timing and success of these opportunities are contingent on market conditions and strategic alignment.
What Threats Does BBI Face?
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Clinical trial failures.
- Patent expirations.
What Are BBI's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Clinical trial data supporting the efficacy and safety of its products.
- Strategic collaborations with other companies in the pharmaceutical industry.
What Does BBI Do?
Founded in 2009 and headquartered in Boulder, Colorado, Brickell Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing innovative prescription therapeutics. The company focuses on addressing unmet needs in autoimmune, inflammatory, and other debilitating diseases. Brickell's pipeline includes sofpironium bromide, a late-stage asset for the treatment of primary axillary hyperhidrosis, which has completed Phase III clinical trials. Additionally, the company is developing BBI-02, an oral DYRK1A inhibitor for autoimmune and inflammatory diseases, and BBI-10, a covalent stimulator of interferon genes inhibitor for autoinflammatory and rare genetic diseases. Brickell Biotech operates through license and collaboration agreements with companies like Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc., Dr. Nicholas S. Bodor, and AnGes, Inc., leveraging external expertise to advance its research and development efforts. The company's strategic focus is on identifying and developing novel therapies that can improve the lives of patients suffering from chronic and debilitating conditions.
What Products and Services Does BBI Offer?
- Develop prescription therapeutics for autoimmune diseases.
- Develop prescription therapeutics for inflammatory diseases.
- Develop prescription therapeutics for other debilitating diseases.
- Develop sofpironium bromide for the treatment of primary axillary hyperhidrosis.
- Develop BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases.
- Develop BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases.
- Develop next-generation kinase inhibitors.
How Does BBI Make Money?
- Develops pharmaceutical products through in-house research and development.
- Out-licenses or partners with other companies for further development and commercialization.
- Generates revenue through licensing agreements and potential future product sales.
What Industry Does BBI Operate In?
Brickell Biotech operates within the highly competitive biotechnology industry, characterized by intense research and development, lengthy regulatory approval processes, and significant financial investments. The market for autoimmune and inflammatory disease therapeutics is substantial and growing, driven by an aging population and increasing prevalence of chronic conditions. Competition includes both established pharmaceutical giants and smaller, specialized biotech firms. Brickell Biotech's focus on dermatology and niche indications like hyperhidrosis allows it to target specific market segments, but it also faces challenges in securing funding and navigating the complex regulatory landscape.
Who Are BBI's Key Customers?
- Patients suffering from autoimmune diseases.
- Patients suffering from inflammatory diseases.
- Patients suffering from hyperhidrosis.
- Potential pharmaceutical partners.
Key Financial Metrics
Return on equity for Brickell Biotech, Inc. stands at -66.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -49.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -77.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.98 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -103.0%, the inverse of the P/E and a quick read on earnings relative to price.
Brickell Biotech, Inc. (BBI) Valuation Context
Valued at $7.08M, BBI is classified as a micro-cap stock.
Company Profile
Brickell Biotech, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boulder, US. The company is led by CEO Robert Brown. BBI has traded publicly since 1993.
Financial Health
Brickell Biotech, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -7.21 places it in the distress zone, a signal of elevated financial risk.
BBI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in BBI's future prospects, indicating that management believes in the company's potential.
- Positive community sentiment has emerged around BBI's latest drug developments, with discussions highlighting promising trial results.
- Analysts are noting increasing interest from institutional investors, which often signals a shift in market perception toward a bullish outlook.
- Social media platforms are buzzing with optimism regarding BBI's upcoming product launches, reflecting a growing belief in the company's growth trajectory.
Bear Case
- Concerns about the competitive landscape have surfaced, with some analysts questioning BBI's ability to maintain market share against larger players.
- Recent discussions indicate skepticism about the pace of regulatory approvals, which could delay product launches and impact investor sentiment.
- Negative sentiment has been noted regarding the company's cash burn rate, raising worries about its financial sustainability in the short term.
- A few prominent voices in the trading community are expressing doubts about the efficacy of BBI's treatments, which could dampen enthusiasm among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BBI Latest News
No recent news available for BBI.
Leadership: Robert Brown
CEO
Robert Brown is the Chief Executive Officer of Brickell Biotech, Inc. His background includes experience in managing and leading pharmaceutical companies, with a focus on strategic development and commercialization. He is responsible for overseeing the company's operations, driving its growth strategy, and managing its relationships with key stakeholders. His leadership is crucial for navigating the challenges of the biotechnology industry and achieving the company's goals.
Track Record: Under Robert Brown's leadership, Brickell Biotech has focused on advancing its clinical pipeline, particularly sofpironium bromide. Key milestones include the completion of Phase III clinical trials for sofpironium bromide and the continued development of BBI-02 and BBI-10. His strategic decisions have been instrumental in securing partnerships and collaborations to support the company's research and development efforts.
Brickell Biotech, Inc. Healthcare Stock: Key Questions Answered
What happened to Brickell Biotech, Inc. (BBI) stock?
Brickell Biotech, Inc. (BBI) no longer trades on public markets. It was delisted in September 2022. The figures below are historical and are not a current quote.
Can I still buy BBI shares?
No. BBI stopped trading on public markets in September 2022, so the shares are not available through a broker. Anything you see quoted for BBI elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before BBI stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Brickell Biotech, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Brickell Biotech, Inc. do?
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing prescription therapeutics for autoimmune, inflammatory, and other debilitating diseases. Their lead product candidate, sofpironium bromide, is being developed for the treatment of primary axillary hyperhidrosis (excessive underarm sweating) and has completed Phase III clinical trials.
What are the main risks for BBI?
The main risks for Brickell Biotech, Inc. are typical of a clinical-stage pharmaceutical company. These include the risk of clinical trial failures, regulatory setbacks, and competition from other companies developing similar therapies.
What is Brickell Biotech, Inc.'s drug pipeline status?
Brickell Biotech's lead candidate, sofpironium bromide, has completed Phase III clinical trials for primary axillary hyperhidrosis, positioning it closest to potential commercialization pending regulatory approval. BBI-02, an oral DYRK1A inhibitor, is in preclinical development for autoimmune and inflammatory diseases, and BBI-10, a covalent STING inhibitor, is also in preclinical stages for autoinflammatory and rare genetic diseases.
How does Brickell Biotech, Inc. navigate regulatory approval processes?
As a clinical-stage company, Brickell Biotech's future hinges on successful navigation of regulatory pathways. For sofpironium bromide, this involves submitting a New Drug Application (NDA) to the FDA, based on the positive Phase III trial results. The company must demonstrate the drug's safety and efficacy, as well as its manufacturing quality.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis pending for BBI.